HCM Quote, Financials, Valuation and Earnings

Pharmaron Beijing has a net margin of -- compared to HUTCHMED (China)'s net margin of --. HUTCHMED (China)'s return on equity of 4.99% beat Pharmaron Beijing's return on equity of --.

HUTCHMED (China) has a consensus price target of $26.43, signalling upside risk potential of 63.86%. On the other hand Pharmaron Beijing has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) has higher upside potential than Pharmaron Beijing, analysts believe HUTCHMED (China) is more attractive than Pharmaron Beijing.

HUTCHMED (China) has a beta of 0.772, which suggesting that the stock is 22.752% less volatile than S&P 500. In comparison Pharmaron Beijing has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharmaron Beijing offers a yield of 1.46% to investors and pays a quarterly dividend of $0.03 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Pharmaron Beijing pays out -- of its earnings as a dividend.

HUTCHMED (China) quarterly revenues are --, which are smaller than Pharmaron Beijing quarterly revenues of --. HUTCHMED (China)'s net income of -- is lower than Pharmaron Beijing's net income of --. Notably, HUTCHMED (China)'s price-to-earnings ratio is 80.65x while Pharmaron Beijing's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 4.47x versus 1.44x for Pharmaron Beijing. Usually stocks with elevated PS ratios are considered overvalued.

Prenetics Global has a net margin of -- compared to HUTCHMED (China)'s net margin of -137.21%. HUTCHMED (China)'s return on equity of 4.99% beat Prenetics Global's return on equity of -23.16%.

HUTCHMED (China) has a consensus price target of $26.43, signalling upside risk potential of 63.86%. On the other hand Prenetics Global has an analysts' consensus of $13.00 which suggests that it could grow by 202.33%. Given that Prenetics Global has higher upside potential than HUTCHMED (China), analysts believe Prenetics Global is more attractive than HUTCHMED (China).

HUTCHMED (China) has a beta of 0.772, which suggesting that the stock is 22.752% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.

HUTCHMED (China) quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. HUTCHMED (China)'s net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, HUTCHMED (China)'s price-to-earnings ratio is 80.65x while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 4.47x versus 2.07x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.

Regencell Bioscience Holdings has a net margin of -- compared to HUTCHMED (China)'s net margin of --. HUTCHMED (China)'s return on equity of 4.99% beat Regencell Bioscience Holdings's return on equity of --.

HUTCHMED (China) has a consensus price target of $26.43, signalling upside risk potential of 63.86%. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) has higher upside potential than Regencell Bioscience Holdings, analysts believe HUTCHMED (China) is more attractive than Regencell Bioscience Holdings.

HUTCHMED (China) has a beta of 0.772, which suggesting that the stock is 22.752% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend.

HUTCHMED (China) quarterly revenues are --, which are smaller than Regencell Bioscience Holdings quarterly revenues of --. HUTCHMED (China)'s net income of -- is lower than Regencell Bioscience Holdings's net income of --. Notably, HUTCHMED (China)'s price-to-earnings ratio is 80.65x while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 4.47x versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Sino Biopharmaceutical has a net margin of -- compared to HUTCHMED (China)'s net margin of --. HUTCHMED (China)'s return on equity of 4.99% beat Sino Biopharmaceutical's return on equity of 10.53%.

HUTCHMED (China) has a consensus price target of $26.43, signalling upside risk potential of 63.86%. On the other hand Sino Biopharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) has higher upside potential than Sino Biopharmaceutical, analysts believe HUTCHMED (China) is more attractive than Sino Biopharmaceutical.

HUTCHMED (China) has a beta of 0.772, which suggesting that the stock is 22.752% less volatile than S&P 500. In comparison Sino Biopharmaceutical has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.55%.

HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical offers a yield of 2.42% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Sino Biopharmaceutical pays out 27.13% of its earnings as a dividend. Sino Biopharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

HUTCHMED (China) quarterly revenues are --, which are smaller than Sino Biopharmaceutical quarterly revenues of --. HUTCHMED (China)'s net income of -- is lower than Sino Biopharmaceutical's net income of --. Notably, HUTCHMED (China)'s price-to-earnings ratio is 80.65x while Sino Biopharmaceutical's PE ratio is 24.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 4.47x versus 2.03x for Sino Biopharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.